FAIR ACT
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill expands a neutral technical change provision: 2. Findings Congress finds the following: Patients in the United States often face significant delays in accessing innovative medicines compared to patients in other trusted, reduces a grant, reporting req, compliance mandate provision: 3, and reduces a grant, reporting req, compliance mandate provision: 524C. Reciprocal marketing approval for certain drugs A covered product with reciprocal marketing approval in effect under this section is deemed to be. It relies on grants, compliance mandates, reporting requirements, and definition changes. The main policy areas are Healthcare.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Expands a neutral technical change provision: 2. Findings Congress finds the following: Patients in the United States often face significant delays in accessing innovative medicines compared to patients in other trusted...
- Reduces a grant, reporting req, compliance mandate provision: 3.
- Reduces a grant, reporting req, compliance mandate provision: 524C. Reciprocal marketing approval for certain drugs A covered product with reciprocal marketing approval in effect under this section is deemed to be...
- Expands a grant, compliance mandate, definition change provision: 4.
- Expands a grant, compliance mandate, definition change provision: 569B–1.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
The bill expands a neutral technical change provision: 2. Findings Congress finds the following: Patients in the United States often face significant delays in accessing innovative medicines compared to patients in other trusted, reduces a grant, reporting req, compliance mandate provision: 3, and reduces a grant, reporting req, compliance mandate provision: 524C. Reciprocal marketing approval for certain drugs A covered product with reciprocal marketing approval in effect under this section is deemed to be.
Key Policy Areas
Healthcare
Primary Purpose
The bill expands a neutral technical change provision: 2. Findings Congress finds the following: Patients in the United States often face significant delays in accessing innovative medicines compared to patients in other trusted, reduces a grant, reporting req, compliance mandate provision: 3, and reduces a grant, reporting req, compliance mandate provision: 524C. Reciprocal marketing approval for certain drugs A covered product with reciprocal marketing approval in effect under this section is deemed to be.
Policy Domains
Sponsors
Legislative Progress
In CommitteeReferred to the House Committee on Energy and Commerce.
Introduced in House
Mr. Sessions (for himself and Mr. Peters) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology